The drug, Dimebon, was originally used as an antihistamine, but early trials have shown that it may actually reverse some symptoms of Alzheimer's.
Thursday, drug giant Pfizer agreed to invest $225 million into the small San Francisco-based biotech Medivation, which owns the rights to Dimebon. The two companies will now partner on the development of the drug as they seek FDA approval.
